Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan-Feb;5(1):47-53.
doi: 10.1002/mdc3.12553. Epub 2017 Sep 22.

Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort

Samantha K Holden  1 , Taylor Finseth  2 , Stefan H Sillau  1 , Brian D Berman  1   3
Affiliations

Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort

Samantha K Holden et al. Mov Disord Clin Pract. 2018 Jan-Feb.

Abstract

Background: The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established.

Objective: Determine progression rates of MDS-UPDRS scores in de novo PD.

Methods: 362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of de novo PD, were included. Longitudinal progression of MDS-UPDRS total and subscale scores were modeled using mixed model regression.

Results: MDS-UPDRS scores increased in a linear fashion over five years in de novo PD. MDS-UPDRS total score increased an estimated 4.0 points/year, Part I 0.25 points/year, Part II 1.0 points/year, and Part III 2.4 points/year.

Conclusions: The expected average progression of MDS-UPDRS scores in de novo PD from this study can assist in clinical monitoring and provide comparative data for detection of disease modification in treatment trials.

Keywords: MDS-UPDRS; Parkinson disease; biomarkers; disease progression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression of scores on Parts I, II , III , and total of the Movement Disorder Society‐Sponsored Revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS ) in the Parkinson's Progression Markers Initiative ( PPMI ) cohort. SE indicates standard error.
Figure 2
Figure 2
Progression of scores on Part III (motor part) of the Movement Disorder Society‐Sponsored Revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS ) in the medicated and unmedicated Parkinson's Progression Markers Initiative ( PPMI ) groups. SE indicates standard error.
See this image and copyright information in PMC

References

    1. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1:189–195. - PMC - PubMed
    1. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002;17:867–876. - PubMed
    1. Martinez‐Martin P, Gil‐Nagel A, Gracia LM, Gomez JB, Martinez‐Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994;9:76–83. - PubMed
    1. Rabey JM, Bass H, Bonuccelli U, et al. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997;20:322–337. - PubMed
    1. Stebbins GT, Goetz CG, Lang AE, Cubo E. Factor analysis of the motor section of the Unified Parkinson's Disease Rating Scale during the off‐state. Mov Disord 1999;14:585–589. - PubMed